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Abstract
Connective tissue growth factor (CTGF) is a secreted protein that is strongly induced in human and experimental heart
failure. CTGF is said to be profibrotic; however, the precise function of CTGF is unclear. We generated transgenic mice and
rats with cardiomyocyte-specific CTGF overexpression (CTGF-TG). To investigate CTGF as a fibrosis inducer, we performed
morphological and gene expression analyses of CTGF-TG mice and rat hearts under basal conditions and after stimulation
with angiotensin II (Ang II) or isoproterenol, respectively. Surprisingly, cardiac tissues of both models did not show increased
fibrosis or enhanced gene expression of fibrotic markers. In contrast to controls, Ang II treated CTGF-TG mice displayed
preserved cardiac function. However, CTGF-TG mice developed age-dependent cardiac dysfunction at the age of 7 months.
CTGF related heart failure was associated with Akt and JNK activation, but not with the induction of natriuretic peptides.
Furthermore, cardiomyocytes from CTGF-TG mice showed unaffected cellular contractility and an increased Ca2+ reuptake
from sarcoplasmatic reticulum. In an ischemia/reperfusion model CTGF-TG hearts did not differ from controls. Our data
suggest that CTGF itself does not induce cardiac fibrosis. Moreover, it is involved in hypertrophy induction and cellular
remodeling depending on the cardiac stress stimulus. Our new transgenic animals are valuable models for reconsideration
of CTGF’s profibrotic function in the heart.
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Introduction
Heart failure is an increasing health problem worldwide [1]. The
mortality rate averages 30% within the first year after diagnosis
irrespective of treatment [1,2]. Heart failure has numerous causes;
however, the major pathomechanisms are universal [3]. The cardiac
remodeling cascade involves initiation of adaptive cellular hypertro-
phy followed by left ventricular dilatation, decreased systolic
function, cardiomyocyte loss, and development of fibrosis. The
profibrotic and prohypertrophic changes in the heart are mainly
driven by transforming growth factor-b (TGF-b) [4,5,6].Connective
tissue growth factor (CTGF; also known as CCN2) is an extracellular
matrix-secreted protein that is induced by TGF-b [7,8]. The protein
belongs to the highly conserved CCN family (Cyr61, CTGF, and
NOV) of growth factors that exerts a wide range of biological
functions [9,10]. CTGF regulates such diverse cellular processes as
extra-cellular matrix (ECM) deposition, wound repair, angiogenesis,
migration, and differentiation, as well as cell survival and
proliferation [9]. However, the most prominent feature of CTGF
is its overexpression in fibrosis of various organs including lung,
kidney, skin, and heart [11,12,13,14,15,16,17,18,19]. Angiotensin II
(Ang II), epinephrine, and mechanical stress induce CTGF in
cultured cardiomyocytes [18,20]. Other studies showed that CTGF
also exhibited prohypertrophic properties on cardiomyocytes [21].
Furthermore, serum CTGF has been proposed as a heart failure
biomarker [19,22]. The diversity of findings regarding CTGF and its
role in heart failure prompted us to investigate CTGF function in
two different rodent models of CTGF overexpression in the heart.
Results
Expression and localization of CTGF in CTGF-TG animals
We constructed a transgene using the mouse MLC-2 promoter,
rabbit b-globin exon 2, intron 2 and exon 3, rat CTGF cDNA and
a polyA signal SV40-virus (Figure 1A). We obtained a transgenic
mouse and a transgenic rat line, which showed an abundant
expression of CTGF mRNA and protein in the heart but not in
other tissues (Figure 1B, C and supplemental Figure S1A, S1B).
The overexpression of rat CTGF cDNA in the mouse allowed us
to distinguish between endogenous CTGF expression and CTGF
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mRNA derived from the transgene. As shown by quantitative
Taqman-PCR with specific CTGF mouse and rat primers and
probes, the endogenous CTGF expression was strongly induced in
CTGF-TG mouse hearts (Figure 1D) indicating an autocrine
mechanism driving the CTGF expression in the heart. As shown
by immunohistochemistry CTGF was marginally expressed in WT
hearts (Figure 1E) while in the transgenic heart ventricles CTGF
was abundantly present in the interstitial space (Figure 1E). No
CTGF specific staining signal was observed in non-hypertensive
WKY-control rats (Figure 1E) or in control staining performed
without primary anti-CTGF-antibody (data not shown). In
comparison, hearts from 6-months-old spontaneously hypertensive
rats (SHR) displayed a pronounced hypertrophy and fibrosis
accompanied by high CTGF upregulation with a similar
localization in the interstitial space (data not shown).
Age-dependent heart failure in CTGF-TG mice
CTGF-TG mice and rats developed normally and had no
immediate increased mortality. To investigate the role of CTGF in
cardiac performance we examined mice by echocardiography over
time (Figure 2D). At 3 months of age, the average LVEDD and
LVESD as well as FS were similar in control and CTGF-TG mice
(Figure 2A). Compensatory hypertrophy, dilatation, and finally
loss of contractility became apparent at a later age. At age of 4
months, the LVEDD reached an average value of 3.9 mm in
transgenic mice, compared to 4.2 mm in normal littermates
(p,0.01). Similarly, a reduction of LVESD and an increase of
PWTD, both significant, were observed indicating a hypertrophic
change in the left heart chamber architecture. These changes were
associated with a slight but not significant increase in FS
(Figure 2B). Hypertrophy was followed by ventricular dilatation
at the age of 7 months: the CTGF-TG mice developed remarkably
increased ventricular diameters (Figure 2C) and a severe loss of the
cardiac function compared to WT animals (Figure 2C, 2D). Thus,
CTGF overexpression in cardiomyocytes caused age-dependent
heart dysfunction with a disease course going from compensatory
hypertrophy to ventricular dilatation and systolic heart failure.
CTGF does not induce cardiac fibrosis in murine or rat
hearts
Since a large body of evidence implicates CTGF as a profibrotic
factor, we addressed the question whether CTGF overexpression
would induce cardiac fibrosis. In CTGF-TGmice and rats no fibrotic
changes were detectable as assessed byMasson’s trichrome and Sirius
red stainings (Figure 3A and supplemental Figure S1C and S1E).
Accordingly, the mRNA levels of collagen 1a, collagen 3, and
Figure 1. Construction of cardiomyocyte-specific CTGF-TG mice. (A) Schematic structure of the transgene. 1 and 2 indicate primers used for
genotyping and 3 and 4 show primers used to generate the probe for CTGF ribonuclease protection assay. MLC-2 (myosin light chain-2) promoter;
rabbit b-globin exon 2 and 3 for enhanced expression of the transgene; SV40 pA, polyadenylation signal from Simian virus 40. (B) Expression of CTGF
mRNA in hearts (He) and other organs (kidney, lung, liver, brain) of transgenic mice shown by ribonuclease protection assay. (C) Western Blot analyses
of CTGF protein overexpression in CTGF-TG mouse hearts. GAPDH protein expression was used as loading control. (D) Quantification of the
transgenic and endogenous CTGF mRNA expression by TaqMan PCR. (WT n= 4, TG n= 4; *, P,0.05 (E) Histological staining of CTGF in WT and CTGF-
TG mice as well as in Wistar-Kyoto rats (WKY) as control for spontaneously hypertensive rat (SHR). Scale bars designate a length of 100 mm.
doi:10.1371/journal.pone.0006743.g001
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fibronectin were not increased in CTGF-TG mice and rats
(Figure 3B, 3C and supplemental Figure S1D). Yet, an increased
diameter of murine CTGF-TG cardiomyocytes could be detected by
tissue structural analyses in hearts from 7 months old mice
(Figure 3D). Taken together, overexpression of CTGF in cardiomy-
ocytes did not induce fibrosis neither in murine nor in rat hearts, but
was rather associated with hypertrophic changes at the cellular level.
CTGF overexpression is associated with Akt- and JNK-
activation
To elucidate the cellular mechanisms underlying the observed
phenotype in CTGF-TG mice, we determined the mRNA
expression levels of two hypertrophy markers, atrial natriuretic
peptide (ANP) and brain natriuretic peptide (BNP). TaqMan real
time PCR showed no changes in the ANP and BNP expression
between WT and transgenic mice at 4 and 7 months of age
(Figure 4A and 4B). To further examine whether CTGF initiates
hypertrophic signals immunoblot analyses were performed on
lysates from 7-month-old murine hearts with phospho-specific
antibodies. As shown in Figure 4C CTGF-TG hearts displayed an
activation of the Akt and JNK pathways. These data suggest that
the cardiac changes in transgenic mice were associated with the
activation of the Akt and JNK pathways but were independent of
ANP and BNP expression.
CTGF overexpression preserves the cardiac function
under Ang II-induced pressure overload conditions
In WT mice, echocardiography revealed a significant reduction
in systolic function after Ang II infusion, as indicated by decreased
FS (Figure 5A). This reduction was almost completely abrogated in
treated CTGF-TG animals (Figure 5A). In CTGF-TG mice, the
contractile performance after Ang II was preserved to the level of
mice receiving only a sham infusion. As expected after Ang II
infusion, the ratio PWTD/LVEDD was increased (Figure 5B).
However, these increases were not different between WT and
CTGF-TG mice. The subsequent stainings showed an increased
degree of fibrosis, which was not different between CTGF-TG
mice and controls (Figure 5C). Accordingly, collagen 1a mRNA
was elevated in WT and transgenic animals after treatment with
Ang II, but both groups were similarly affected (Figure 5C). The
mRNA quantification of the hypertrophy markers ANP and BNP
showed a significant increase after Ang II infusion (Figure 5D).
However, there were no significant differences between CTGF-
TG and WT mice. Altogether, these data suggest that CTGF
overexpression has a beneficial effect on cardiac function in an
acute pressure-overload heart failure model. This protection is not
due to elevated levels of ANP and BNP. Moreover, the CTGF
overexpression does not affect the development of cardiac fibrosis
under hypertrophic conditions.
Figure 2. Characterization of CTGF-TG mice of different ages by echocardiography. (A, B, C) Measurements of LVEDD, LVESD, calculated
ratio of PWD/LVEDD and FS of 3-months-old mice (A, WT n= 9 TG n=7), 4-months-old mice (B, WT n= 10, TG n= 9) and 7-months-old mice (C, WT
n= 7, TG n=6). * P,0.05; ** P,0.01; *** P,0.001. (D) Examples of M-mode echocardiography in CTGF-TG and WT mice at age of 7 months.
doi:10.1371/journal.pone.0006743.g002
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Figure 3. Assessment of cardiac fibrosis at age of 4 and 7months in CTGF-TG andWTmice. (A) Masson’s trichrome stained cardiac sections
of WT and CTGF-TG mice at age of 4 and 7 months. Scale bars designate a length of 100 mm. (B, C) Quantification of the collagen 1a, collagen 3 and
fibronectin mRNA expression by TaqMan-PCR performed at age of 4- (B) and 7 months (C) (n = 4 per group). (D) High magnifications of toluidine blue-
stained semithin sections, with myofiber hypertrophy apparent in 7 months old CTGF-TG hearts. Scale bars designate a length of 20 mm.
doi:10.1371/journal.pone.0006743.g003
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Improved Ca2+ handling in CTGF TG cardiomyocytes
To further elucidate the cellular mechanisms in CTGF-TG
hearts at a single cell level, we characterized intracellular Ca2+
transients of isolated cardiomyocytes. The recordings of contrac-
tion kinetics of single cardiomyocytes at 3 months of age revealed
that the basal cell length and contractile function were similar in
transgenic and WT cardiomyocytes (supplemental Figure S2). In
both groups, we observed a comparable FS as well as similar
contraction and relaxation rates (supplemental Figure S2A-S2D).
In order to record the intracellular Ca2+-transient, we loaded
cardiomyocytes with Ca2+-sensitive Fura-2 dye and observed a
slightly, but robustly reduced cytosolic Ca2+-content in diastole in
transgenic cardiomyocytes compared to WT cells (supplemental
Figure S2E-S2H). These results indicate an improved diastolic
Figure 4. Quantification of expression and activation of cardiac hypertrophy markers. (A, B) Quantification of ANP and BNP mRNA
expression by TaqMan-PCR in 4- (A) and 7 months (B) old mice (n = 4 per group). (C) Quantitative analysis of the phosphorylation status of Akt and
JNK at age of 7 months. The band intensities of Akt- or JNK-phosphoproteins are normalized with those of unphosphorylated Akt or unspecific bands
respectively.
doi:10.1371/journal.pone.0006743.g004
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clearance of Ca2+ from the cytosol in CTGF-TG cardiomyocytes.
Further, we assayed the Ca2+ transient amplitude and the velocity
of Ca2+ influx and -efflux from sarcoplasmatic reticulum. Yet, the
last parameters were not found to be changed in transgenic
cardiomyocytes. Taken together, overexpression of CTGF in
cardiomyocytes is accompanied by an enhanced Ca2+ clearance
Figure 5. Characterisation of cardiac function, fibrosis and hypertrophy under pressure overload conditions (3.5 months of age). (A,
B) Echocardiographic measurements of fractional shortening (A) and interventricular septum diameter in diastole (B) in WT (n = 10) and CTGF-TG
(n = 11) mice treated with Ang II (*p,0.05; ** p,0.01, *** p,0.001) (C) Masson’s trichrome stained cardiac sections of mice treated with Ang II and
quantification of collagen 1amRNA expression by Taqman-PCR. (D) Quantification of ANP and BNP mRNA expression by TaqMan-PCR in mice treated
with Ang II (n = 4 per group).
doi:10.1371/journal.pone.0006743.g005
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from the cytosol. However, at this time point the modification of
the Ca2+ cycling is not reflected in an altered cellular contractility.
CTGF-overexpression and acute ischemia
Several studies reported an upregulation of CTGF upon
ischemic conditions.[23,24] In order to examine the effects of
CTGF overexpression on the ischemic heart disease, we subjected
isolated CTGF-TG and WT mouse hearts to 40 minutes ischemia
with subsequent 60 minutes reperfusion phase. In the setting of the
working heart model, we monitored the left ventricular pressures
and contraction- and relaxation rates at baseline as well as after
ischemia and reperfusion. Interestingly, the CTGF-TG and WT
hearts displayed similar intracardiac pressures under basal
conditions as well as under ischemia and reperfusion (supplemen-
tal Figure S3A and S3B). Similar results were obtained in respect
to contraction and relaxation rates (supplemental Figure S3C and
S3D). All together, these data suggest, that CTGF overexpression
does not play a role in the immediate physiological response of the
heart to ischemia. In addition, the acute recovery process is not
affected by CTGF overexpression.
Discussion
We produced transgenic mice and rats with cardiomyocyte-
restricted overexpression of CTGF and found that CTGF alone
does not induce cardiac fibrosis, but rather exerts a prohyper-
trophic function. Transgenic mice and rats abundantly expressed
the CTGF protein in the interstitial space of the right and left
ventricles. The secretion of CTGF from cardiomyocytes to the
interstitium is in accordance with the localization of CTGF
observed in hearts from spontaneously hypertensive rats, another
model with significant CTGF upregulation. These findings
confirm the physiological distribution of transgenic CTGF and
support the suitability of our models for the analysis of CTGF
function in the heart. Moreover, we observed in CTGF-TG mouse
hearts an increased expression of the endogenous mRNA, which
points to an autocrine enhancement of the CTGF regulation. This
finding mirrors data published by Yokoi and colleagues,
demonstrating an increased endogenous CTGF expression in
kidney overexpressing transgenic CTGF [15]. Furthermore,
CTGF administration also stimulates CTGF expression in
cultured mesangial cells [25].
CTGF is felt to be one of the key profibrotic factors mediating
the TGF-b profibrotic action. Surprisingly, the overexpression of
CTGF in cardiomyocytes did not result in increased development
of cardiac fibrosis neither under basal nor under hypertrophic
conditions. We carefully assayed the development of fibrosis in
both transgenic models by use of various methods. Our
morphological observations were confirmed by collagen 1a,
collagen 3, and fibronectin mRNA quantification, which also did
not reveal significant changes between WT and transgenic hearts.
These findings are in line with results obtained from CTGF
overexpression in kidney, which also did not result in renal fibrosis
under basal conditions [15]. Even after induction of diabetes in
this model, no changes in the expression level of key ECM
inducers like fibronectin, collagen 4A1 and 4A3 were detected.
Benniaud and colleagues transiently overexpressed CTGF in lung
using the adenoviral gene transfer [26]. In their study, a drastic
CTGF overexpression induced a moderate pulmonary fibrosis
suggesting CTGF as an indirect profibrotic factor. The cell type
overexpressing CTGF may play a crucial role in the observed
phenotype. Despite cardiomyocyte specific CTGF overexpression,
we believe, that secretion of the protein allows it to exert its
physiological function also on cardiac fibroblasts. It would be
certainly intriguing to overexpress CTGF specifically in cardiac
fibroblasts; however, a specific promoter for this cell type is not
available until now. Interestingly, Mori at al. tested the fibrotic
response of CTGF-null embryonic fibroblasts upon TGF-b
stimulation. This study revealed CTGF to be dispensable for the
TGF-b induced fibrotic response in embryonic fibroblasts [27]. In
conclusion, our results and other studies support the hypothesis,
that CTGF itself is not a fibrosis inducer. However, the protein
may play a role as a profibrotic cofactor under certain conditions.
Given the possibility that CTGF is involved in contractile
function and hypertrophy, we examined CTGF-TG mice by
echocardiography. We observed an age dependent presence of
cardiac hypertrophy, which was followed by ventricular dilatation
at the age of 7 months. This phenotype was accompanied by an
increased activation of the prohypertrophic Akt Kinase but
surprisingly not by an increase of ANP and BNP expression.
These findings are consistent with data published by Hyata et al.,
who showed hypertrophic effects of CTGF stimulation on
cardiomyocytes in vitro [21]. The authors also demonstrated that
hypertrophic changes of cultured cardiomyocytes were accompa-
nied by upregulation of skeletal actin and BNP when induced by
endothelin-1, but not after stimulation with CTGF. Furthermore,
the study showed, that Akt activation is required for CTGF-
mediated induction of hypertrophy. Interestingly, recent studies
have demonstrated that Akt plays an important role in the
determination of cardiac myocytes size [28]. Recently, transient
activation of Akt in the heart was reported to result in adaptive/
physiological hypertrophy while longer periods of Akt activation
were detrimental and led to dilated cardiomyopathy [28]. These
observations provide a possible explanation for the disease course
observed in our CTGF-TG model. While the initial overexpres-
sion of CTGF activates Akt triggering adaptive hypertrophy, the
prolonged CTGF overexpression tips the balance towards heart
failure.
If overexpression of CTGF initially enhances cardiac adaptive
response, the CTGF overexpressing hearts should display
improved remodeling in acute cardiomyopathy. To test this
hypothesis, we employed infusion of Ang II for 14 days as a model
of acute pressure overload. In fact, echocardiography revealed a
strong decrease of systolic function in WT mice, while CTGF-TG
hearts showed preserved cardiac function that was similar to that
of sham-treated animals. These results suggest a role of CTGF in
the induction of cardiac adaptive response and its function as a
protective factor in acute cardiomyopathy. An interpretation of
these results is that CTGF plays a role as an early prohypertrophic
factor that mildens or delays heart failure by reducing transmural
wall tension. Such an adaptive hypertrophic response would
transiently improve cardiac performance. However, in the course
of progressive heart failure, the continuous expression of CTGF
becomes enhanced through autocrine and paracrine regulation
triggering an increased activation of prohypertrophic pathways
like the Akt kinase pathway. Thus, a certain basal CTGF
expression might have a beneficial effect on cardiac performance
while long-term CTGF upregulation leads to ‘‘overstimulation’’
and activation of pathological pathways resulting in loss of
cardiomyocytes and ventricular dilatation.
The altered contractile performance of CTGF-TG hearts may
also be attributed to a modified Ca2+ handling in cardiomyocytes.
To get a comprehensive picture of the cellular mechanisms
accompanying the phenotypical changes in CTGF overexpressing
hearts, we analyzed the Ca2+ metabolism and cardiomyocyte
mechanisms at single cell level. Myocyte contraction and
relaxation are under the control of the rise and decline in
cytosolic Ca2+ levels [29]. The rise in intracellular free Ca2+
CTGF Overexpression and Heart
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initiates contraction through the binding of Ca2+ to myofilaments,
whereas myocyte relaxation is promoted by decrease in intracel-
lular Ca2+ and dissociation of Ca2+ from the myofilaments.
Although the cellular contractility at age of 3 months did not differ
between the CTGF-TG and WT cardiomyocytes, we observed an
increased reuptake of Ca2+ from the cytosol in CTGF-TG
myocytes. A consequence of an increased Ca2+ reuptake might
be an enhanced contractile function. However, we suggest that the
observed changes in Ca2+ metabolism may promote increased
contractility under stress conditions like upon Ang II stimulation.
Lowering in cytosolic Ca2+ is accomplished mainly by Ca2+
sequestration into the sarcoplasmatic reticulum by SERCA2a and
Ca2+ extrusion from the cell by the Na+/Ca2+-Exchanger [30]. To
elucidate the contribution of both pathways to the increased Ca2+
reuptake in CTGF overexpressing cardiomyocytes, further
experiments need to be done.
Several studies implicate CTGF as a factor being involved in
tissue remodeling after myocardial infarction, but its physiological
function in ischemia and following muscle recovery remains
elusive [23,24,31]. Therefore, the present study also focused on
this functional aspect of CTGF. In the working heart model we
observed a similar reduction of contractility under ischemic
conditions in CTGF-TG and WT hearts. Moreover, the recovery
of contractile function after reperfusion was comparable in both
groups. These results suggest that CTGF does not play an
immediate physiological role in acute ischemic and postischemic
events. We rather assume that CTGF exerts its function in later
postischemic phase, where its expression is strongly induced. Dean
et al. reported on major increases in CTGF mRNA and protein
occurring in the viable myocardium at 180 days after myocardial
infarction [31].
In summary, our current study presents evidence that CTGF
itself does not induce fibrosis, but rather is a protein involved in
adaptive cardiac mechanisms like cellular hypertrophy and Ca2+
metabolism modification. Although CTGF is broadly accepted as
a profibrotic factor, there are no in vivo studies showing a clear
causality between CTGF overexpression and fibrosis induction. So
far, the major evidence for the profibrotic action of CTGF is based
on the fact, that fibrotic events are accompanied by CTGF
upregulation. Thus, we believe that our data provide good reason
to reconsider the profibrotic role of CTGF particularly in the heart
shedding new light on the functional diversity of this protein.
However, detailed mechanisms of CTGF action will require
further studies.
Materials and Methods
Generation of CTGF-transgenic mice (CTGF-TG)
We generated cardiac-directed transgenic rat (Sprague-Dawley)
and mouse (FVB/N).
The full-length rat CTGF cDNA was amplified with following
primers (59-cggaattcgctgtgcgtcctcctgccg-39 and 59-cgggatcc-
gagttcgtgtcccttactcc-39) and cloned into a vector containing the
mouse myosin light chain-2 promoter (MLC-2) and a region of the
rabbit b-globin gene containing exon 2, intron 2 and exon 3. The
construct was linearized and microinjected into the male
pronucleus of mouse and rat zygotes as described [32]. The
identification of founder animals and further genotyping were
conducted by PCR using the primers 59-atgttatatggagggggcaaagtt-
39 and 59-tccacgccagccagaat-39. Animals were kept in the
hemizygote state. All animals used in this study were males. All
experimental protocols were performed in accordance with the
guidelines for the humane use of laboratory animals by the Max-
Delbru¨ck Center for Molecular Medicine and were approved by
local German authorities with standards corresponding to those
prescribed by the American Physiological Society.
Echocardiography and Angiotensin II (Ang II) infusion
A two-dimensional short axis view of the left ventricle was
obtained with a 45-MHz transducer (Sonic Vevo 770 High-
Resolution Imaging System, Toronto, Canada) from Isofluran
anesthetized mice. M-mode tracings were recorded and used to
determine the diameter of the left ventricle at the end of the
diastole (LVEDD) and systole (LVESD). Fractional shortening
(FS) corresponds to the value of (LVEDD-LVESD)/LVEDD.
In 3.5-months-old mice we infused Ang II (1.4 mg/kg/day) for
14 days by Alzet osmotic pumps (Alzet, Cupertino, USA)
implanted subcutaneously. All animal studies were carried out
in accordance with the local authorities and conforming to the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals.
Analysis of mRNA Expression
Total RNA was extracted from organs by using TRIzol reagent
according to the manufacturer’s instructions (Invitrogen, Carlsbad,
USA). An antisense probe for CTGF was 32P-UTP-labeled by in
vitro transcription (Riboprobe combination system Sp6/T7;
Promega, Madison, USA). RNA expression was measured by
RNase protection assay (RPA II kit, Ambion, Austin, USA).
Protected fragments were separated on a polyacrylamide gel and
detected with a Fuji phospho-imager (Fujix BAS 2000, Fuji,
Tokyo, Japan). The quantification of ANP, BNP, collagen 1a,
collagen 3, fibronectin, and GAPDH was carried out by Taqman-
PCR. The total RNA was reverse-transcribed with oligo(dT)
primers (Gibco-BRL, Carlsbad, USA) and Omniscript reverse
transcriptase (Qiagen, Hilden, Germany). Primers and probes
were designed using Primer Express 2.0 (Applied Biosystems,
Foster City, USA). Expression levels of all genes were normalized
to GAPDH RNA expression by using the 2(2DDCT) method. To
compare samples the DCt-mean of the wild type group was used as
a calibration sample.
Histological Analysis
Hearts from 4- or 7-months-old CTGF-TG or control animals
were perfused with 4% paraformaldehyde and embedded in
paraffin. Longitudinal sections (10 mm) were stained with
Masson’s trichrome and Sirius red. For high magnification
pictures heart tissue was perfused with 4% paraformaldehyde
and postfixed with 2.5% glutaraldehyde in PBS for 48 hours.
Samples were stained with 1% OsO4 for 2 h, dehydrated in a
graded ethanol series and propylene oxide and embedded in Poly/
BedR 812 (Polysciences, Inc., Eppelheim, Germany). Semithin
sections (1 mm) from 7 months old animals were stained with
toluidine blue. For CTGF-specific staining, hearts were cryo-
preserved, cut in longitudinal sections (8 mm) and mounted onto
SuperFrost Plus slides (Menzel, Braunschweig, Germany). The
sections were fixed with cold acetone, washed with TBS, and
incubated for 30 minutes in a humid chamber at room
temperature with 10% normal donkey serum (Jackson ImmunoR-
esearch, West Grove, USA) and washed again with TBS.
Subsequently sections were incubated for 60 minutes with
polyclonal anti-CTGF primary antibody (1:500; Santa Cruz,
Santa Cruz, USA). The Cy3-conjugated anti-goat IgG was uses as
secondary antibody (1:500; Jackson ImmunoResearch, West
Grove, USA). Fluorescence images were collected using Axioplan2
imaging microscope and a Sensicam 12BIT camera (Zeiss, Jena,
Germany).
CTGF Overexpression and Heart
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Western Blot
Hearts from 7-months-old CTGF-TG and control mice were
homogenized in RIPA-protein extraction buffer and denatured in
SDS-loading buffer (Roth, Karlsruhe, Germany) at 95uC for 5
minutes. SDS-PAGE was carried out and blotted on PVDF-
membranes (Amersham, Little Chalfon, UK). Membranes were
blocked with 5% (w/v) dried milk in 100 mmol/L Tris, pH 7.5,
0.1% (v/v) Tween 20 and 150 mmol/L NaCl (TBST) for 1 h
prior to overnight incubation at 4uC with anti-CTGF, anti-
phospho-Akt or anti-phospho-JNK (Cell Signaling, Danvers, USA)
antibody as a first antibody. To quantify the extend of Akt
phosphorylation and CTGF expression, the membrane was
reprobed with anti-Akt antibody (Cell Signaling, Danvers, USA)
or anti-GAPDH, respectively. The band intensities of Akt-
phospho-protein were normalized with those of total Akt-protein.
The level of JNK phosphorylation was normalized for band
intensities of unspecific bands. The expression of CTGF was
normalized with GAPDH expression.
Working heart model
Three months old mice were anaesthetized with 4% chloralhy-
drate (Sigma Aldrich, Taufkirchen, Germany) and injected with
5,000 U/kg heparin. After thoracotomy, hearts were quickly
removed, the aorta cannulated, and connected to the perfusion
apparatus (Hugo Sachs electronic, March-Hugstetten, Germany).
They were perfused retrogradally with Krebs-Henseleit solution
(KH; mM concentrations: 118 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2
MgSo4, 1.2 KH2PO4, 0.5 EDTA, 25 NaHCO3, 5.5 glucose,
pH 7.4, 37uC) with a constant pressure of 50 mmHg (Langendorff
mode). A Millar tip catheter was inserted into the left ventricle for
measurements of pressure development and its derivatives. A small
catheter was placed into the left atrium through the pulmonary
vein for perfusion of the left atrium with KH at constant pressure
of 10–11 mmHg (flow around 5 mL/min; preload). Registration
was than switched from retrograde to anterograde perfusion
(working heart mode). The perfusate exited the left ventricle
through the aortic cannula, which was connected to a pressure
chamber with an air cushion for the windkessel function. Aortic
pressure was set to 50 mmHg (afterload). The heart was
electrically paced with a constant frequency of 320 beats/min
and was subjected to 40 minutes baseline perfusion, 40 minutes
ischemia followed by 60 minutes reperfusion. Recordings were
performed in the last 7 minutes of each phase. Signals were
recorded, stored, and evaluated using software HEM (version 3.2,
Notocord System).
Isolation of adult primary cardiomyocytes
Male wild-type or CTGF-TG mice (3-months-old) were
anaesthetized with isoflurane followed by intraperitoneal injection
of 8 mg xylazine and 35 mg ketamine. Hearts were rapidly
removed, transferred into 10 ml 0.9% NaCl solution containing
1,000 U heparin, and connected to a cannula in a Langendorff
perfusion system. Hearts were perfused at 37uC for 3 minutes with
Ca2+-free Krebs-Henseleit buffer (KHB: 127 mM NaCl, 4.6 KCl,
1.2 KH2PO4, 24.8 NaHCO3, 1.1 MgSO4, 8.3 glucose, 10
butanedione monoxime, pH 7.4, 37uC) gassed with carbogen.
After that, perfusion was switched to recirculation with KH
containing 0.04% collagenase (Worthington Biochemical Corpo-
ration, Lakewood, USA), and 0.2% bovine serum albumin. After
27 minutes, the hearts were pale and soft. The ventricles were
minced and incubated in the digestion medium (0,23% BSA,
0.04% collagenase in KH solution) for another 10 minutes at
37uC. After filtration through a nylon mesh (200 mm pore size)
and centrifugation, cells were resuspended in Ca2+-free medium.
Ca2+ concentration was increased stepwise to 500 mmol/L in
order to obtain Ca2+-tolerant cardiomyocytes. After final washes,
cardiomyocytes were resuspended in M199 medium supplemented
with 0.2% bovine serum albumin, 5% fetal calf serum, 5 mmol/L
creatine, 5 mmol/L taurine, 2 mmol/L carnitine, 10 mmol/L
cytosine-D-arabinofuranoside, and antibiotics. Cardiomyocytes
were seeded in laminin-coated 4-well chamber slides (Nunc,
Wiesbaden-Schierstein, Germany) specialized for microscopic
contractility and fluorescence measurement, and cultured for
4 hours in M199 medium.
Measuring cell shortening and Ca2+ transients
Attached cardiomyocytes were washed with Hank’s balanced
salts solution buffered with 10 mM Hepes at pH 7.4 (HBSS). Cells
were loaded with fura-2-AM for 30 minutes at room temperature
in the dark. Dye solution was removed, and cells were left on
HBSS for another 15 minutes. Cell shortening and fura-signals
were simultaneously measured at 30uC on an Ionoptix contrac-
tility and fluorescence system (Ionoptix, Milton, USA). Cardio-
myocytes were electrically field-stimulated with bipolar pulses of
5 ms duration at 1 Hz. Cell shortening, expressed as percentage of
resting cell length, was measured using the video-edge technique at
a sampling rate of 240 per second. Ca2+ transients were monitored
as ratio of fluorescence emission at 510 nm obtained by alternate
excitation at 340 and 380 nm (340/380 ratio). Data files from 15
consecutive beats recorded at intervals were averaged for analysis.
Statistical analysis
Differences between two groups were evaluated by using
unpaired Student’s t-test and Mann-Whitney U-test. Differences
between more than two groups were evaluated by using ANOVA
followed by Fisher’s probable least-squares difference test using
Prism software (Graphpad Software, La Jolla, USA). The
significance level was set at p,0.05. All data are expressed as
mean6SEM.
Supporting Information
Figure S1 Fibrosis development in CTGF-TG rats and mice. (A)
Expression of CTGF mRNA in heart of transgenic rats shown by
ribonuclease protection assay. (B) Western Blot analyses of CTGF
protein overexpression in CTGF-TG rat hearts. GAPDH protein
expression was used as loading control. (C) Sirius red staining of
fibrotic tissue in left ventricle of WT and CTGF-TG rat as well as
CTGF-TG and WT rat treated with isoproterenol. (D) Quanti-
fication of the collagen 1a, collagen 3, and fibronectin mRNA
expression by TaqMan-PCR performed in 4-months-old rats
(n = 5 per group). (E) Sirius red stained cardiac sections of WT and
CTGF-TG mice at age of 4 and 7 months as well as WT mice
treated with isoproterenol as positive control (WT-mouse-ISO).
Scale bars designate a length of 50 mm.
Found at: doi:10.1371/journal.pone.0006743.s001 (13.94 MB
TIF)
Figure S2 Measurements of Ca2+-cycling and contractile
function in single isolated cardiomyocytes at age of 3 months.
Isolated murine cardiomyocytes were measured for (A) baseline
cellular length, (B) FS, (C) contraction and (D) relaxation rate. The
Ca2+-cycling was assessed by recording of such parameters like (E)
cytosolic Ca2+ content in diastole, (F) amplitude of the Ca2+
wave, (G) velocity of the Ca2+ influx and (H) efflux from the
cytosol. CTGF-TG cardiomyocytes n= 43, WT cardiomyocytes
n = 38.
Found at: doi:10.1371/journal.pone.0006743.s002 (0.58 MB TIF)
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Figure S3 Characterization of cardiac function at 3 months of
age in ischemia/reperfusion model. The left ventricular pressures
were assessed during 5 minutes of each phase (baseline, ischemia
and reperfusion). We monitored (A) intracardiac pressure in systole
(ICPsys), (B) intracardiac pressure in diastole (ICPdia), (C)
contraction rate (ICPsys/sec), and (D) relaxation rate (ICPdia/
sec), n = 7 mice per group.
Found at: doi:10.1371/journal.pone.0006743.s003 (0.60 MB TIF)
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